Eikon’s pipeline has the potential to deliver important new medicines to people living with serious diseases, including programs now in the clinic designed to improve cancer treatment, and preclinical programs spanning immunology, neuroscience and oncology.

Our team brings clinical and regulatory experience, advanced engineering, sophisticated data analysis, breakthrough research utilizing AI-powered super-resolution microscopy, and consistent scientific rigor to our drug development pipeline.

Clinical Assets

TLR7/8 – BDB001

BDB001 is a systemically administered immune modulator and agonist of toll-like receptors 7 and 8. This program has demonstrated single-agent activity as well as activity in combination with anti-PD-(L)1 agents across multiple solid tumor types in Phase 1 trials, where over 150 patients have been treated to date. In the current landscape of novel immuno-oncology entrants, single-agent efficacy is rare and meaningful, as it suggests the new agent alone contributes significantly to the enhancement of immune responses to tumors. We plan to advance this program rapidly through clinical study across multiple solid tumor indications.

PARP1 Selective Inhibitors – IMP1734 and IMP17307 

These molecules selectively target PARP1, a central component of the DNA repair machinery in normal cells. Selective inhibition of PARP1 could potentially be at least equally efficacious when compared with the currently approved PARP1/2inhibitors, without the toxicity thought to be associated with PARP2 inhibition. We intend to bring IMP1734 into the clinic in the near future, guided by the prior experience of our team in the development of previously approved PARP1/2 inhibitors. 

Our second, earlier stage selective PARP1 asset, IMP17307, is differentiated by its ability to cross the blood-brain barrier and potentially treat cancers in the brain. We continue to conduct studies designed to permit this program to enter the clinic.

Preclinical Programs

Our pipeline also includes programs spanning oncology, immunology and neuroscience at various stages of preclinical development. We have a particular focus on programs targeting:

  • Steroid hormone receptors in both oncology and inflammation, including our programs for the androgen receptor and its v7 splice variant, which emerges in a meaningful subset of patients suffering from advanced prostate cancer
  • Elements of the DNA Damage Response, including PARP1, WRN and other undisclosed programs
  • Transcription factors and immune modulators across therapeutic areas 

These preclinical programs strongly complement our pioneering discovery platform, translating the measurement of protein population dynamics into discoveries that will enable the invention of important new medicines.